Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
25 December 2020 - 12:30AM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”), a company focused on the creation of the Terra
CoV-2 vaccine candidate to combat the novel coronavirus pandemic,
today announced it has entered into definitive agreements with
investors for the purchase and sale of 14,444,444 shares of its
common stock at a purchase price of $0.45 per share in a registered
direct offering. The closing of the offering is expected to occur
on or about December 29, 2020, subject to the satisfaction of
customary closing conditions.
A.G.P./Alliance Global Partners is acting as sole placement
agent for the offering.
This offering is being made pursuant to an effective shelf
registration statement on Form S-3 (File No. 333- 235763)
previously filed with the U.S. Securities and Exchange Commission
(the “SEC”). A prospectus supplement describing the terms of the
proposed offering will be filed with the SEC and will be available
on the SEC’s website located at http://www.sec.gov. Electronic
copies of the prospectus supplement may be obtained, when
available, from A.G.P./Alliance Global Partners, 590 Madison
Avenue, 28th Floor, New York, NY 10022, or by telephone at (212)
624-2060, or by email at prospectus@allianceg.com. Before investing
in this offering, interested parties should read in their entirety
the prospectus supplement and the accompanying prospectus and the
other documents that the Company has filed with the SEC that are
incorporated by reference in such prospectus supplement and the
accompanying prospectus, which provide more information about the
Company and such offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Oragenics, Inc.
Oragenics, Inc. is focused on the creation of the Terra CoV-2
vaccine candidate to combat the novel coronavirus pandemic and the
further development of effective treatments for novel antibiotics
against infectious disease. The Company is dedicated to the
development and commercialization of a vaccine candidate providing
specific immunity from novel coronavirus. The Terra CoV-2
immunization leverages coronavirus spike protein research conducted
by the National Institute of Health. In addition, Oragenics has an
exclusive worldwide channel collaboration with ILH Holdings, Inc.
(n/k/a Eleszto Genetika, Inc.), relating to the development of
novel lantibiotics.
Forward-Looking Statements
This press release contains “forward-looking statements” as
defined in the Private Securities Litigation Reform Act of 1995, as
amended, that involve significant risks and uncertainties about
Oragenics, including but not limited to statements with respect to
the completion, timing, size, and use of proceeds of the proposed
underwritten offering of common stock. Oragenics may use words such
as “expect,” “anticipate,” “project,” “intend,” “plan,” “aim,”
“believe,” “seek,” “estimate,” “can,” “focus,” “will,” and “may”
and similar expressions to identify such forward-looking
statements. Among the important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are risks relating to, among other
things, whether or not Oragenics will be able to raise capital, the
final terms of the registered direct offering of common stock,
market and other conditions, the satisfaction of customary closing
conditions related to the registered direct offering of common
stock, Oragenics’ business and financial condition, and the impact
of general economic, industry or political conditions in the United
States or internationally. For additional disclosure regarding
these and other risks faced by Oragenics, see disclosures contained
in Oragenics’ public filings with the SEC, including the “Risk
Factors” in the company’s Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q, and prospectus for this offering. You should
consider these factors in evaluating the forward-looking statements
included in this press release and not place undue reliance on such
statements. The forward-looking statements are made as of the date
hereof, and Oragenics undertakes no obligation to update such
statements as a result of new information, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201224005153/en/
Oragenics, Inc. Corporate: Michael Sullivan, 813-286-7900
Chief Financial Officer msullivan@oragenics.com or
Investors: John Marco Managing Director CORE IR 516-222-2560
johnm@coreir.com or Media: Jules Abraham CORE IR
917-885-7378 julesa@coreir.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From May 2023 to May 2024